Sumitomo Mitsui Trust Group sold 217,377 shares of Twist Bioscience Corporation (NASDAQ: TWST) during Q1 2026, reducing its position by approximately 19% according to regulatory filings. The Japanese financial giant's divestment, worth roughly $11 million at current trading levels, signals continued institutional caution around the DNA synthesis sector as competition intensifies and margins compress.

The sale leaves Sumitomo Mitsui with approximately 930,000 shares, down from over 1.14 million shares held at year-end 2025. This represents the trust's largest single-quarter reduction in its Twist position since initially building the stake in 2023. The timing coincides with broader institutional rotation away from high-growth synthetic biology platforms as investors reassess valuations amid rising interest rates.

Institutional Sentiment Shifts on DNA Synthesis

The Sumitomo Mitsui reduction reflects growing skepticism about Twist's premium valuation relative to emerging competitors. While the company pioneered commercial-scale DNA synthesis using silicon-based synthesis arrays, newer entrants are challenging its cost structure and turnaround times.

DNA Labs, a private competitor backed by Andreessen Horowitz, recently claimed 48-hour synthesis times for 2kb constructs at 40% lower pricing than Twist's standard offering. Meanwhile, Ansa Biotechnologies raised $48 million in Series B funding for its enzymatic DNA synthesis platform, which promises further cost reductions through elimination of traditional phosphoramidite chemistry.

Twist's Q4 2025 results showed synthetic biology revenue declining 8% year-over-year to $42.1 million, with management citing "pricing pressure from competitors and customer inventory destocking." The company's gross margins in the synthetic biology segment compressed to 23%, down from 31% in Q4 2024.

Market Dynamics Pressure Traditional Players

The institutional sell-off comes as the DNA synthesis market experiences rapid transformation. Traditional players like Twist face pressure from multiple directions: cloud-based design platforms reducing synthesis volumes, in-house capabilities at major pharma companies, and next-generation synthesis technologies offering superior economics.

Ginkgo Bioworks has been particularly aggressive in developing internal synthesis capabilities, reducing its reliance on external vendors by approximately 60% over the past 18 months. The company's Foundry Services division now handles most routine DNA assembly work internally, putting pressure on Twist's bread-and-butter oligo synthesis business.

Benchmark analyst David Westenberg noted in a recent report: "Twist's moat was deeper when synthesis was a bottleneck. As capacity proliferates and costs fall, differentiation becomes harder." He maintained a Hold rating with a $45 price target, citing execution risks in the company's pivot toward data storage applications.

Strategic Pivot Faces Execution Challenges

Twist has been attempting to diversify beyond traditional synthetic biology customers through its DNA data storage initiative. The company signed a $25 million pilot program with Microsoft Azure in late 2025 to demonstrate exabyte-scale archival storage using synthetic DNA.

However, the data storage business remains pre-commercial with significant technical hurdles. Current read/write speeds are roughly 1,000x slower than magnetic tape storage, while costs remain prohibitive for most applications. Industry experts estimate commercial viability requires another 3-5 years of technology development and cost reduction.

The company's antibody discovery platform, acquired through its $300 million Abveris purchase in 2024, has shown more promise. The platform generated $18.2 million in revenue during Q4 2025, representing 43% year-over-year growth. However, this segment faces intense competition from computational antibody design platforms like those developed by Generate Biomedicines and AbCellera.

Key Takeaways

  • Sumitomo Mitsui Trust Group reduced its Twist Bioscience position by 19%, selling 217,377 shares worth approximately $11 million
  • The sale reflects broader institutional caution around DNA synthesis companies facing increased competition and margin compression
  • Twist's synthetic biology revenue declined 8% year-over-year in Q4 2025, with gross margins falling to 23%
  • New competitors like DNA Labs and Ansa Biotechnologies are challenging Twist's pricing power with faster, cheaper synthesis platforms
  • The company's strategic pivot toward DNA data storage and antibody discovery faces significant technical and commercial execution risks

Frequently Asked Questions

Why did Sumitomo Mitsui sell its Twist Bioscience shares? The Japanese trust group likely reduced its position due to concerns about increasing competition in the DNA synthesis market and Twist's declining margins. The company faces pressure from newer, more cost-effective synthesis platforms.

How does this sale affect Twist Bioscience's stock price outlook? Large institutional sales can create downward pressure on stock prices and signal reduced confidence in the company's prospects. However, the impact depends on overall market sentiment and company execution on strategic initiatives.

What competitors are challenging Twist's market position? Key competitors include DNA Labs (backed by Andreessen Horowitz), Ansa Biotechnologies with their enzymatic synthesis platform, and integrated players like Ginkgo Bioworks developing internal capabilities.

Is Twist's DNA data storage business commercially viable? The DNA data storage business remains pre-commercial with significant technical challenges. Current technology is roughly 1,000x slower than magnetic tape storage, and commercial viability likely requires 3-5 years of additional development.

What is Twist's strategy to maintain market leadership? Twist is diversifying into antibody discovery through its Abveris acquisition and pursuing DNA data storage applications. The company is also investing in next-generation synthesis technologies to maintain cost competitiveness.